NASDAQ:NRXS NeurAxis (NRXS) Stock Price, News & Analysis $6.80 -0.20 (-2.86%) Closing price 04:00 PM EasternExtended Trading$6.94 +0.14 (+1.99%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About NeurAxis Stock (NASDAQ:NRXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NeurAxis alerts:Sign Up Key Stats Today's Range$6.74▼$7.2050-Day Range$6.67▼$8.8152-Week Range$2.20▼$9.33Volume92,549 shsAverage Volume151,324 shsMarket Capitalization$84.21 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders. NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements. Its lead programs are designed to modulate key pathways involved in neuronal survival and regeneration, with preclinical and early-stage clinical studies underway to assess safety, pharmacokinetics and proof of concept. Headquartered in the United States, NeurAxis engages with international partners to support its translational and clinical development activities. The company’s common shares trade on the Nasdaq Stock Market under the ticker symbol NRXS.AI Generated. May Contain Errors. Read More Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXS Stock News HeadlinesNeuraxis (NRXS) Stock Forecast & Price TargetJune 17, 2026 | investing.comNeurAxis Stockholders Approve Directors and Equity Compensation PlansJune 12, 2026 | tipranks.comFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear market is now warning of a coming financial breakdown unlike anything most Americans have seen in their lifetimes. Editor Michael Salvatore of TradeSmith Daily is going public with a new warning - and specific recommendations for what to do with your wealth right now.June 24 at 1:00 AM | TradeSmith (Ad)NeurAxis Earnings Call Highlights Growth and HurdlesMay 22, 2026 | theglobeandmail.comNeurAxis (NRXS) Climbs on Reimbursement and Guideline MomentumMay 18, 2026 | insidermonkey.comNeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/YMay 15, 2026 | finance.yahoo.comNeurAxis, Inc. (NRXS) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comNeurAxis, Inc.: NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue GrowthMay 12, 2026 | finanznachrichten.deSee More Headlines NRXS Stock Analysis - Frequently Asked Questions How have NRXS shares performed this year? NeurAxis' stock was trading at $4.54 at the start of the year. Since then, NRXS stock has increased by 49.8% and is now trading at $6.80. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.25) earnings per share for the quarter. The company had revenue of $0.67 million for the quarter. When did NeurAxis IPO? NeurAxis (NRXS) raised $7 million in an IPO on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share. Who are NeurAxis' major shareholders? Top institutional investors of NeurAxis include Money Concepts Capital Corp (1.96%), Renaissance Technologies LLC (0.67%), Elevation Point Wealth Partners LLC (0.10%) and Royal Bank of Canada (0.08%). Insiders that own company stock include Brian Allen Carrico, Thomas Joeseph Carrico, Timothy Robert Henrichs and Corp Masimo. View institutional ownership trends. How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeurAxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Outdoor (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI). Company Calendar Last Earnings11/12/2024Today6/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:NRXS CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees19Year Founded2011Price Target and Rating Average Price Target for NeurAxis$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+91.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.63 million Net Margins-492.76% Pretax Margin-341.35% Return on EquityN/A Return on Assets-641.25% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.23 Sales & Book Value Annual Sales$4.28 million Price / Sales19.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-25.19Miscellaneous Outstanding Shares12,384,000Free Float6,085,000Market Cap$84.21 million OptionableNot Optionable Beta1.42 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:NRXS) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
